14091

$XTALPI(02228.HK)

Based on the aforementioned in-depth research, we present a clear core conclusion:

The current timing calls for [maintaining positions] (and adding to positions at dips during volatile pullbacks / optimizing portfolio structure), rather than systematically reducing exposure.

The Hong Kong innovative medicine sector has completed industrial clearing and undergone a fundamental qualitative shift, entering a golden window period of advancing from historically extremely low valuations to an earnings-driven upward cycle. The core supporting logic for this judgment is as follows:

1. Valuation is at an absolute bottom; downside risk is locked in (high payoff ratio)

The valuation discount for Hong Kong biopharma assets has reached extreme historical levels. Currently, the price-to-sales ratio (PS-TTM) for Hang Seng Tech and related biotech assets is approximately 2.3x, and the P/E ratio (PE-TTM) is around 20x, both sitting in the bottom 10% of their five-year historical percentiles. Current secondary market prices have already priced in extreme pessimism regarding geopolitical frictions and macro liquidity disturbances. The risk of further significant compression in valuations is very limited, providing a solid margin of safety.

2. Industry fundamentals have crossed the break-even line; endogenous cash-generating capability is established (high certainty)

In contrast to the past phase of relying on external financing to "burn cash and paint pie charts," leading Chinese innovative drug companies have fully entered a "period of earnings realization" supported by actual sales revenue and cash flow:

Alright, AI has found me reasons to hold. I'll close my eyes and ignore XtalPi, shifting my attention back to the great crypto circle $iShares Bitcoin Trust ETF(IBIT.US) $IShares Ethereum Trust ETF(ETHA.US)